ACADIA Pharmaceuticals (ACAD) Baird's 2024 Global Healthcare Conference summary

Company overview and financials

• Commercial-stage biotech focused on neuroscience and rare diseases, with two marketed products: Nuplazid and Daybue.

• Nuplazid targets Parkinson's disease psychosis, with 2024 net sales guidance around $600 million.

• Daybue treats Rett syndrome, with expected 2024 sales between $340 million and $370 million.

• Cash flow positive, holding over $500 million in cash and no debt as of Q2.

• Business development is a strategic priority, aiming to expand the portfolio and sustain growth.

Nuplazid franchise and growth strategy

• Nuplazid is in its mid-life cycle, with focus on maximizing cash flow and profitability.

• Real-world evidence studies show mortality benefit and lower healthcare utilization compared to off-label antipsychotics.

• Recent label clarification improved physician understanding, supporting growth.

• Disease awareness and direct-to-consumer campaigns launched to boost patient and caregiver engagement.

• Growth from these initiatives expected to materialize over the next two years.

Nuplazid market and intellectual property

• About 130,000 U.S. patients diagnosed with Parkinson's disease psychosis at any time.

• Patent protection extends to 2030 (composition of matter, pending pediatric extension) and 2037 (formulation/method of use).

• Recent legal victories strengthen IP position; ongoing litigation continues.